Testing the drug atezolizumab in people whose glioblastoma has come back
Official title: A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a drug called atezolizumab in people whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Read our full plain-language summary
What the trial team says
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Key facts
- Registry number
- NCT06069726
- Stage of testing
- Phase 2
- Conditions studied
- Recurrent Glioblastoma
Where it is running
This trial lists 4 sites.
-
California
- University of California, San Francisco (San Francisco)
-
Missouri
- Saint Luke's Cancer Institute (Kansas City)
-
North Carolina
- Duke University (Durham)
-
Utah
- Huntsman Cancer Institute (Salt Lake City)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.